Publication for Hmgcr and Pmvk

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
mmu	Hmgcr	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	15357			[link]
mmu	Pmvk	phosphomevalonate kinase	68603

Pubmed ID	Priority	Text
23299886	0.98	Hmgcr, Mvk, Pmvk, Mvd, Fdft1 and Sqle/Erg1 in the cholesterol biosynthetic pathway are decreased in SRSF3HKO liver.
	0.87	Hmgcr, Mvk, Pmvk, Dhcr7, Erg1, Fdft1 and Mvd is not seen in the Xbp1 liver knockout.
21631939	0.98	Hmgcr, Pmvk, Idi1, Fdps, and Lss, were all up-regulated between 1.3 to 3.0 fold at the transcript level.
22252456	0.98	Hmgcr, Pmvk, Mvd, Fdps, Nsdhl, Idi1, Sc4mol, Cyp51, and Dhcr7).
22303341	0.98	3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr, the gene encoding the rate-limiting enzyme for cholesterol synthesis, -1.9-fold change) and phosphomevalonate kinase (Pmvk, the gene encoding the protein that catalyzes the fifth condensation reaction in cholesterol synthesis, -2.0-fold change; see Figure 4F).
27255552	0.98	Hmgcr, Pmvk, Sqle and Sc4mol) which target SREBP; a major transcriptional regulator of cholesterol metabolism.
30069000	0.98	Hmgcr, Hmgcs1, Hsd17b7, Idi1, Lss, Mvd, Mvk, Msmo1, Nsdhl, Pmvk, Sc5d, Sqle, and Tm7sf2 were significantly decreased in HFD livers.
30580099	0.98	Hmgcr, Hmgcs1, Pmvk and Acat2 (Fig. 3F).
31327168	0.98	Hmgcr, Acss2, Pmvk, Mvd, Fdft1, Ldlr, and Sqle (Figure 2A).
30334382	0.97	HMGCR and upregulations of cholesterol synthesis enzymes mevalonate kinase (Mvk), phosphomevalonate kinase (Pmvk), farnesyl-diphosphate farnesyltransferase 1 (Fdft1/Sqs), and squalene epoxidase (Sqle).
23139832	0.91	Hmgcr, Idi1, Fdps, Sqle, Dhcr7 and Pmvk), including Hmgcr - that is the gene encoding the rate limiting enzyme for cholesterol biosynthesis - were up-regulated at 4-wk..Upstream regulator analysis indicated that SREBF2, SREBF1, SIRT2, FOXO1, EGR2, PPARGC1B were predicted "active", whereas PPARA, CEBPE, HMGA1and WT1 were predicted "inhibit" (Table S5).
28694924	0.86	HMGCR protein, respectively; (2) treatment of all 3 statins also led to greater expression of SREBP-2 gene and some of its downstream targets (e.g., mevalonate kinase, phosphomevalonate kinase, farnesyl-diphosphate farnesyltransferase 1 and squalene epoxidase); and (3) plasma concentrations of 3 cholesterol surrogates (e.g., lathosterol, lanosterol and desmosterol) failed to accurately reflect the rates of cholesterol synthesis in statin-treated mice.
20054815	0.76	Hmgcr, Pmvk, and Fdps.